Dose Density in Breast Cancer: A Simple Message?
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Oncology
Link
http://academic.oup.com/jnci/article-pdf/97/23/1712/7687074/dji438.pdf
Reference17 articles.
1. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist2001 ; 6 (suppl 3): 30 –5.
2. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol2003 ; 21 : 1431 –9.
3. Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst2005 ; 97 : 1724 –33.
4. Seidman AD, Berry D, Cirrincone C, Harris L, Dressler L, Muss H, et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol2004 ; 22 (14S): 512 .
5. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol2005 ; 23 : 5983 –92.
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer;Science Translational Medicine;2016-02-24
2. Biweekly docetaxel-containing chemotherapy may be the optimal schedule;Anti-Cancer Drugs;2008-04
3. Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives;Breast Care;2008
4. Progress in the Treatment of Early and Advanced Breast Cancer;Breast Cancer
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3